RE:Merck loses ground to SummitActually, Keytruda is owned by the US version of Merck. Whereas TLD1433 is manufactured by Sigma Aldrich a division of the original Merck Group of Germany. Two separate companies. Even so I suspect Merck USA is watching TLT.
In 1891, Georg(e) Merck established himself in the United States and set up
Merck & Co. with Theodore Weicker in New York. Merck & Co. was confiscated following WW1 and set up as an independent company in the United States. Today, the US company, which operates as Merck Sharp and Dohme (MSD) outside the U.S. and Canada, has about 68,000 employees (December 2021) in 120 countries. It is one of the top 5 pharmaceutical companies worldwide, larger than its German ancestor, which employs 60,334 people in 67 countries (December 2021). While Merck in Darmstadt is the legal successor of the original Merck and retains the rights to the name "Merck" in all countries except the U.S. and Canada, it is sometimes known as the "German Merck" or "Merck Darmstadt" in North America.
Longholder99 wrote: Competition in the lung cancer arena has Summit Therapeutics Ivonescimab outperforming Keytruda in NSCLC. Gee.....if I was the Merck Board and I was reading all this discussion about Ruvidar (since Merck is manufacturing it) and my stock price just dropped on this news. What would I do about it?